Journal of Thrombosis and Thrombolysis

, Volume 41, Issue 3, pp 384–393 | Cite as

Thromboinflammatory response and predictors of outcomes in patients undergoing transcatheter aortic valve replacement

  • Travis R. Sexton
  • Eric L. Wallace
  • Amy Chen
  • Richard J. Charnigo
  • Hassan K. Reda
  • Khaled M. Ziada
  • John C. Gurley
  • Susan S. Smyth


Transcatheter aortic valve replacement (TAVR) has been increasingly used to treat patients with symptomatic aortic stenosis. Despite improvements in valve deployment, patients that have undergone TAVR are at high risk for major adverse events following the procedure. Blood cell numbers, platelet function, and biomarkers of systemic inflammation were analyzed in 58 patients undergoing TAVR with the Edward’s SAPIEN valve. Following valve deployment, platelet count and agonist-induced platelet activity declined and plasma markers of systemic inflammation (interleukin-6 and S100A8/A9) increased. Baseline platelet activity prior to TAVR correlated with perioperative changes plasma interleukin-6 levels. Moreover, perioperative changes in plasma inflammatory markers predicted the decline in platelet count in the days following the TAVR procedure. Additionally, a significant effect of gender on platelet count following TAVR and was observed. Finally, post-procedural mortality was associated with sustained thrombocytopenia after TAVR. Our findings suggest that TAVR elicits a thromboinflammatory state that may contribute to post-procedural thrombocytopenia. Importantly, our results add to the growing body of literature that suggests the thromboinflammatory changes that occur early after TAVR may predict long-term outcomes.


Platelet Inflammation Transcutaneous aortic valve replacement Inflammation 



TRS was supported in part by T32HL091812 from the Heart Lung and Blood Institute, National Institutes of Health. SSS receives support from CTSA UL1TR000117. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.



Supplementary material

11239_2015_1326_MOESM1_ESM.docx (16 kb)
Supplementary material 1 (DOCX 15 kb)
11239_2015_1326_MOESM2_ESM.doc (1.8 mb)
Supplementary material 2 (DOC 1807 kb)


  1. 1.
    Gilard M, Eltchaninoff H, Iung B, Donzeau-Gouge P, Chevreul K, Fajadet J et al (2012) Registry of transcatheter aortic-valve implantation in high-risk patients. New Engl J Med 366(18):1705–1715CrossRefPubMedGoogle Scholar
  2. 2.
    Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR et al (2012) Two-year outcomes after transcatheter or surgical aortic-valve replacement. New Engl J Med 366(18):1686–1695CrossRefPubMedGoogle Scholar
  3. 3.
    Masson JB, Kovac J, Schuler G, Ye J, Cheung A, Kapadia S et al (2009) Transcatheter aortic valve implantation: review of the nature, management, and avoidance of procedural complications. JACC Cardiovasc Interv 2(9):811–820CrossRefPubMedGoogle Scholar
  4. 4.
    Thomas M, Schymik G, Walther T, Himbert D, Lefevre T, Treede H et al (2011) One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 124(4):425–433CrossRefPubMedGoogle Scholar
  5. 5.
    Thomas M, Schymik G, Walther T, Himbert D, Lefevre T, Treede H et al (2010) Thirty-day results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: a European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 122(1):62–69CrossRefPubMedGoogle Scholar
  6. 6.
    Halliday BP, Dworakowski R, Brickham B, Wendler O, MacCarthy P (2012) Usefulness of periprocedural bleeding to predict outcome after transcatheter aortic valve implantation. Am J Cardiol 109(5):724–728CrossRefPubMedGoogle Scholar
  7. 7.
    Tamburino C, Capodanno D, Ramondo A, Petronio AS, Ettori F, Santoro G et al (2011) Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation 123(3):299–308CrossRefPubMedGoogle Scholar
  8. 8.
    Rodes-Cabau J, Dauerman HL, Cohen MG, Mehran R, Small EM, Smyth SS et al (2013) Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events. J Am Coll Cardiol 62(25):2349–2359CrossRefPubMedGoogle Scholar
  9. 9.
    Dvir D, Genereux P, Barbash IM, Kodali S, Ben-Dor I, Williams M et al (2014) Acquired thrombocytopenia after transcatheter aortic valve replacement: clinical correlates and association with outcomes. Eur Heart J 35(38):2663–2671CrossRefPubMedGoogle Scholar
  10. 10.
    Flaherty MP, Mohsen A, Moore JB, Bartoli CR, Schneibel E, Rawasia W et al (2015) Predictors and clinical impact of pre-existing and acquired thrombocytopenia following transcatheter aortic valve replacement. Catheter Cardiovasc Interv 85(1):118–129CrossRefPubMedGoogle Scholar
  11. 11.
    Jilaihawi H, Doctor N, Chakravarty T, Kashif M, Mirocha J, Cheng W et al (2015) Major thrombocytopenia after balloon-expandable transcatheter aortic valve replacement: prognostic implications and comparison to surgical aortic valve replacement. Catheter Cardiovasc Interv 85(1):130–137CrossRefPubMedGoogle Scholar
  12. 12.
    Holmes DR Jr, Mack MJ, Kaul S, Agnihotri A, Alexander KP, Bailey SR et al (2012) 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol 59(13):1200–1254CrossRefPubMedGoogle Scholar
  13. 13.
    Gallet R, Seemann A, Yamamoto M, Hayat D, Mouillet G, Monin JL et al (2013) Effect of transcatheter (via femoral artery) aortic valve implantation on the platelet count and its consequences. Am J Cardiol 111(11):1619–1624CrossRefPubMedGoogle Scholar
  14. 14.
    McCabe JM, Huang PH, Riedl LA, Devireddy SR, Grondell J, Connors AC et al (2014) Incidence and implications of idiopathic thrombocytopenia following transcatheter aortic valve replacement with the Edwards Sapien((c)) valves: a single center experience. Catheter Cardiovasc Interv 83(4):633–641CrossRefPubMedGoogle Scholar
  15. 15.
    Williams M, Kodali SK, Hahn RT, Humphries KH, Nkomo VT, Cohen DJ et al (2014) Sex-related differences in outcomes after transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis: insights from the PARTNER Trial (Placement of Aortic Transcatheter Valve). J Am Coll Cardiol 63(15):1522–1528CrossRefPubMedGoogle Scholar
  16. 16.
    Krumsdorf U, Chorianopoulos E, Pleger ST, Kallenbach K, Karck M, Katus HA et al (2012) C-reactive protein kinetics and its prognostic value after transfemoral aortic valve implantation. J Invasive Cardiol 24(6):282–286PubMedGoogle Scholar
  17. 17.
    Sinning JM, Scheer AC, Adenauer V, Ghanem A, Hammerstingl C, Schueler R et al (2012) Systemic inflammatory response syndrome predicts increased mortality in patients after transcatheter aortic valve implantation. Eur Heart J 33(12):1459–1468CrossRefPubMedGoogle Scholar
  18. 18.
    Wu Q, Ren J, Wang G, Li G, Anjum N, Hu D et al (2015) Effect of persistent thrombocytopenia on mortality in surgical critical care patients: a retrospective study. Clin Appl Thromb Hemost. doi: 10.1177/107602961558785 PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Travis R. Sexton
    • 1
  • Eric L. Wallace
    • 1
  • Amy Chen
    • 1
  • Richard J. Charnigo
    • 1
  • Hassan K. Reda
    • 1
  • Khaled M. Ziada
    • 1
  • John C. Gurley
    • 1
  • Susan S. Smyth
    • 1
  1. 1.The Gill Heart InstituteUniversity of KentuckyLexingtonUSA

Personalised recommendations